Lilly's Alimta patent upheld through 2022

1 April 2014
medical_legal_law_big

US pharma major Eli Lilly (NYSE: LLY) says that the US District Court for the Southern District of Indiana has ruled in the company's favor regarding the vitamin dosage regimen patent for its cancer drug Alimta (pemetrexed for injection).

In the case of Eli Lilly and Company v Teva Parenteral Medicines Inc et al, the court ruled the vitamin dosage regimen patent is valid and enforceable. The patent provides intellectual property protection for Alimta until 2022. Alimta's compound patent remains in force through early 2017. The drug generated $2.7 billion sales last year and is the second-largest seller for Lilly, which is facing generic competition for other of its leading products.

US District Judge Tanya Walton Pratt said the generic drug companies failed to show that the patent's claims were invalid for obviousness, noting that the method of administering B12 with folic acid would not have been obvious to a person skilled in oncology or nutrition.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical